Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

用于治疗卵巢癌的主链可降解聚合物-药物缀合物

基本信息

  • 批准号:
    8921139
  • 负责人:
  • 金额:
    $ 49.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-26 至 2017-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents, gemcitabine and paclitaxel. Based on the successful results of the STTR Phase I award, this Phase II proposal details the rationale and research plan for the synthesis and evaluation of in vivo efficacy of two novel macromolecular therapeutics with diverse and complementary mode of action for the treatment of ovarian carcinoma. Their design is based on new, innovative long-circulating backbone degradable N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer - drug conjugates. The polymeric carrier will be composed of alternating HPMA copolymer segments (blocks) and enzymatically degradable oligopeptide sequences. Each construct will contain multiple copies of either gemcitabine or paclitaxel. The drugs are attached to the backbone via a lysosomally degradable spacer that will allow intracellular release and bioactivity. The choice of drugs bodes well for the success of the project. Gemcitabine is a synthetic nucleoside analog of cytidine. Its triphosphate metabolite is incorporated into DNA, thereby stopping cell division. Gemcitabine has demonstrated activity in several ovarian cancer models and has been approved by FDA for combination therapy of ovarian cancer. Paclitaxel is a mitotic inhibitor, which acts by stabilizing microtubules, thereby inhibiting their breakdown during cellular division It is currently indicated as first-line and subsequent therapy for the treatment of advanced stages of ovarian cancer. The long circulating time of the new, innovative backbone degradable carriers will result in augmented tumor accumulation due to the EPR (enhanced permeability and retention) effect. In addition, the combination of two polymer-drug conjugates with diverse mechanisms of action will result in enhanced efficacy of ovarian cancer treatment and minimal adverse effects. The specific aims of the proposal are three-fold: a) To scale up of the synthesis and to characterize backbone degradable HPMA copolymer-drug (gemcitabine and paclitaxel) conjugates containing enzymatically degradable sequences in the backbone and in side chains; b) To establish the maximum tolerated dose (MTD) as well as the acute toxicity of the conjugates and their combination in vivo; and c) To evaluate the biodistribution, clearance, anticancer efficacy and dose escalation studies of the conjugates in vivo. The ultimate goal of this project is to develop an effective and marketable drug combination with a novel drug delivery system for the treatment of ovarian cancer where the drugs are localized at the site of the tumor, adverse effects of chemotherapy are minimized and efficacy maximized.
描述(由申请人提供):该第二阶段 STTR 项目的目的是开发一种用于联合递送两种抗肿瘤药物吉西他滨和紫杉醇的聚合物系统。基于 STTR 一期奖的成功结果,该二期提案详细介绍了两种具有不同和互补作用模式的新型大分子疗法治疗卵巢癌的体内疗效的合成和评估的基本原理和研究计划。他们的设计基于新型、创新的长循环主链可降解N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物-药物缀合物。聚合物载体将由交替的 HPMA 共聚物片段(嵌段)和可酶促降解的寡肽序列组成。每个构建体将包含吉西他滨或紫杉醇的多个副本。这些药物通过溶酶体可降解的间隔物附着在主链上,从而允许细胞内释放和生物活性。药物的选择预示着该项目的成功。吉西他滨是胞苷的合成核苷类似物。其三磷酸代谢物被掺入DNA中,从而阻止细胞分裂。吉西他滨已在多种卵巢癌模型中表现出活性,并已被 FDA 批准用于卵巢癌的联合治疗。紫杉醇是一种有丝分裂抑制剂,通过稳定微管发挥作用,从而抑制细胞分裂过程中的分解。目前被认为是治疗晚期卵巢癌的一线和后续疗法。由于EPR(增强渗透性和保留)效应,新型创新骨干可降解载体的长循环时间将导致肿瘤积累增加。此外,两种具有不同作用机制的聚合物-药物缀合物的组合将增强卵巢癌治疗的功效并最小化副作用。该提案的具体目标有三个: a) 扩大合成规模并表征主链和侧链中含有可酶降解序列的主链可降解 HPMA 共聚物药物(吉西他滨和紫杉醇)缀合物; b) 确定缀合物及其组合的体内最大耐受剂量(MTD)以及急性毒性; c) 评估缀合物的体内生物分布、清除率、抗癌功效和剂量递增研究。该项目的最终目标是开发一种有效且可销售的药物组合,并采用新颖的药物输送系统来治疗卵巢癌,其中药物定位于肿瘤部位,最大限度地减少化疗的副作用并最大限度地提高疗效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JINDRICH H. KOPECEK其他文献

JINDRICH H. KOPECEK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JINDRICH H. KOPECEK', 18)}}的其他基金

Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
  • 批准号:
    8291234
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Drug-Free Macromolecular Therapeutics
无药大分子治疗
  • 批准号:
    10529277
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
  • 批准号:
    8645644
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Drug-Free Macromolecular Therapeutics
无药大分子治疗
  • 批准号:
    9885447
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
  • 批准号:
    8457100
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Drug-Free Macromolecular Therapeutics
无药大分子治疗
  • 批准号:
    10304911
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Drug-Free Macromolecular Therapeutics
无药大分子治疗
  • 批准号:
    10062492
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
  • 批准号:
    8021749
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
用于治疗卵巢癌的主链可降解聚合物-药物缀合物
  • 批准号:
    8779604
  • 财政年份:
    2011
  • 资助金额:
    $ 49.24万
  • 项目类别:
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
治疗前列腺癌的双靶点大分子疗法
  • 批准号:
    7759540
  • 财政年份:
    2008
  • 资助金额:
    $ 49.24万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 49.24万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 49.24万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 49.24万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 49.24万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 49.24万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了